Type 2 Diabetes Trial, Recruiting (NCT05970237)

Type 2 Diabetes Trial, Recruiting NCT05970237 Sponsor: Boryung Pharmaceutical Co., Ltd Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT05970237 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with both type 2 diabetes and high blood pressure, and your doctor is planning to prescribe you Trudapa Tab. or Trudapa M SR Tab.
You are willing to sign a written agreement allowing your personal information to be used for this study.
You are able to understand what the study involves, follow the study instructions, and commit to taking part until the study is finished.

Who may not be able to join:

You have high blood pressure that is caused by another specific medical condition (such as a narrowing of a major blood vessel, a hormone disorder, or a kidney disease) rather than being a primary diagnosis — if you are unsure whether this applies to you, please confirm with the trial site.
You have taken a medication called dapagliflozin within the 4 weeks before your first study visit.
It is expected that you will need to start using insulin injections at some point during the study period.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +82-2-708-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05970237

Sponsor: Boryung Pharmaceutical Co., Ltd

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: +82-2-708-8000

More information: https://clinicaltrials.gov/study/NCT05970237

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with both type 2 diabetes and high blood pressure, and your doctor is planning to prescribe you Trudapa Tab. or Trudapa M SR Tab.
You are willing to sign a written agreement allowing your personal information to be used for this study.
You are able to understand what the study involves, follow the study instructions, and commit to taking part until the study is finished.

Who may not be able to join:

You have high blood pressure that is caused by another specific medical condition (such as a narrowing of a major blood vessel, a hormone disorder, or a kidney disease) rather than being a primary diagnosis — if you are unsure whether this applies to you, please confirm with the trial site.
You have taken a medication called dapagliflozin within the 4 weeks before your first study visit.
It is expected that you will need to start using insulin injections at some point during the study period.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Boryung Pharmaceutical Co., Ltd

Registry

ClinicalTrials.gov

Start date

26 July 2023

Est. completion

21 October 2025

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Target blood pressure control rate; Target blood glucose achievement rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov